SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

24 Jan 2025 Evaluate
The sales figure stood at Rs. 1856.48 millions for the December 2024 quarter. The mentioned figure indicates a growth of about 32.54% as compared to Rs. 1400.74 millions during the year-ago period.Profit for the quarter ended December 2024 rises by 57.05% to Rs. 467.82  millions from Rs. 297.88 millions.The company reported a good operating profit of 680.50 millions compared to 445.54 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 1856.48 1400.74 32.54 5123.76 4121.90 24.31 5703.70 4609.38 23.74
Other Income 20.98 30.65 -31.55 68.40 84.50 -19.05 106.35 94.89 12.08
PBIDT 680.50 445.54 52.74 2000.51 1261.82 58.54 1836.11 1383.87 32.68
Interest 5.07 4.94 2.63 12.69 17.70 -28.31 21.10 30.84 -31.58
PBDT 675.43 440.60 53.30 1987.82 1244.12 59.78 1815.01 1353.03 34.14
Depreciation 49.64 39.60 25.35 143.64 118.96 20.75 158.11 118.15 33.82
PBT 625.79 401.00 56.06 1844.18 1125.16 63.90 1656.90 1234.88 34.17
TAX 157.97 103.12 53.19 468.43 303.32 54.43 465.76 336.30 38.50
Deferred Tax 20.25 6.57 208.22 29.58 21.76 35.94 94.76 29.49 221.33
PAT 467.82 297.88 57.05 1375.75 821.84 67.40 1191.14 898.58 32.56
Equity 160.97 160.97 0.00 160.97 160.97 0.00 160.97 160.97 0.00
PBIDTM(%) 36.66 31.81 15.24 39.04 30.61 27.54 32.19 30.02 7.22

Supriya Lifescience Share Price

637.35 -0.60 (-0.09%)
13-Apr-2026 13:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1658.10
Dr. Reddys Lab 1231.00
Cipla 1212.50
Zydus Lifesciences 922.85
Lupin 2321.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×